Research Progress in microRNA-Based Therapy for Gastric Cancer

Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficac...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2019-12, Vol.12, p.11393-11411
Main Authors: Zhao, Xu, Hu, Gao-Feng, Shi, Yan-Fen, Xu, Wei
Format: Article
Language:English
Subjects:
Anthracyclines
Antineoplastic agents
Cancer
Cancer research
Cancer treatment
Chemotherapy
Drug resistance
Fluorouracil
Health aspects
MicroRNA
Nanoparticles
Ramucirumab
Review
Stomach cancer
Surgery
Therapeutics
Tumors
Vincristine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic therapy is still an urgent problem to overcome. In the past decade, the essential roles of microRNAs (miRNAs) in tumor treatment have been increasingly recognized. In particular, miRNAs were recently shown to reverse the resistance to chemotherapy drugs such as 5-fluorouracil, cisplatin, and doxorubicin. Synthesized nanoparticles loaded with mimics or inhibitors of miRNAs can directly target tumor cells to suppress their growth. Moreover, exosomes may serve as promising safe carriers for mimics or inhibitors of miRNAs to treat GC. Some miRNAs have also been shown to play roles in the mechanism of action of other anti-tumor drugs. Therefore, in this review, we highlight the research progress on microRNA-based therapy in GC and discuss the challenges and prospects associated with this strategy. We believe that microRNA-based therapy has the potential to offer a clinical benefit to GC patients, and this review would contribute to and motivate further research to promote this field toward this ultimate goal.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S221354